In the case of the timing of LM occurrence, 8 patients (18.6%) had LM prior to first-line EGFR-TKI treatment (early onset), while 35 patients (81.4%) developed LM after first-line EGFR-TKI treatment (late onset). This evidence concerns the gene EGFR and lymphangioma.